relation of glutamate and oncology, article.

Riluzole and Sorafenib in patients with advanced solid tumors: a Phase I trial

https://scienmag.com/riluzole-and-sorafenib-in-patients-with-advanced-solid-tumors-a-phase-i-trial/

"

Overexpression of metabotropic glutamate receptor 1 (GRM1) has been implicated in the pathogenesis of multiple cancers. Riluzole, an inhibitor of glutamate release, showed synergistic antitumor activity in combination with the multi-kinase inhibitor sorafenib in preclinical models."